Scancell Holdings plc (LON:SCLP – Get Free Report) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 14.69 and traded as low as GBX 9.63. Scancell shares last traded at GBX 9.70, with a volume of 2,065,240 shares trading hands.
Scancell Stock Performance
The company’s fifty day simple moving average is GBX 12.84 and its two-hundred day simple moving average is GBX 14.66. The company has a market capitalization of £99.83 million, a price-to-earnings ratio of -17.49 and a beta of 0.69. The company has a debt-to-equity ratio of -193.29, a quick ratio of 13.01 and a current ratio of 0.56.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Recommended Stories
- Five stocks we like better than Scancell
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
